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Introduction
A major obstacle to cancer rejection is the failure of T
cells to infiltrate and function within the tumor microen-
vironment (TME). Direct modulation of the TME to pro-
mote T cell homing and activation may enhance tumor
control. Two pilot clinical trials were conducted to test the
hypotheses that either intratumoral interferon-gamma
(IFN-g, Trial A, NCT00977145), or application of a TLR7
agonist, imiquimod (Trial B, NCT01264731) would induce
favorable immune signatures and infiltration of CD8+ T
cells into the TME.
Methods
Eligible patients received 6 injections of a multipeptide mela-
noma vaccine and either (Trial A) 2 million units IFN-g intra-
tumorally once on day 22 (n = 9), or (Trial B) imiquimod
applied topically to superficial metastases daily for 6 weeks
(n = 4). Melanoma metastases were biopsied pretreatment
and at 2 time points during treatment and were evaluated
for: immune-cell infiltration by immunohistochemistry, pro-
tein expression by Luminex assay, and gene expression by
Affymetrix array. T cell responses to vaccination were
assessed from peripheral blood by direct ex vivo IFN-g ELI-
spot assay. Adverse events (CTCAE v4) were recorded.
Results
One patient experienced grade 3 skin ulceration at a
vaccine site (Trial A); otherwise, these combination
approaches were well-tolerated. Based on a preliminary
analysis, CD8+ T cell responses to vaccination were
detected in 77% of patients overall. For Trial A, 2 days
after IFN-g, there was an increase in the TME of IFN-
inducible chemokine CXCL10 (IP-10), and increased
gene expression of the T cell co-stimulatory ligand
SECTM1, the immune regulatory enzyme IDO1, and of
Complement 4A/4B, and MIR-125B1, but CD8+ T cell
infiltration of tumors was not increased. In contrast,
imiquimod induced dramatic upregulation of immune
gene signatures at 3 and 6 weeks; and CD8+ T cell infil-
tration was increased in 75% of patient tumors at
3 weeks.
Conclusions
These findings support the safety of modulating the
TME with intratumoral IFN-g or topical imiquimod.
The data from Trial A are the first to characterize direct
effects of IFN-g on the human melanoma TME, and
they suggest possible roles for SECTM1 in mediating
T cell co-stimulation, while also supporting prior evi-
dence for induction of the immune checkpoint IDO1.
Conversely, imiquimod induced strong immune gene
signatures, and promoted CD8+ T cell infiltration of
tumors. These data support use of imiquimod or other
TLR7 agonists in modulating the TME in conjunction
with other immune therapies, and highlight the need for
better understanding of the processes mediating and
limiting T cell infiltration in the TME.
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